Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Researcher identifies 71 genetic regions newly associated with inflammatory bowel disease

In one of the largest studies of its kind ever conducted, an international team of scientists has thrown new light on the genetic basis of the inflammatory bowel diseases (IBD).

3 Nov 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

Allergies and hygiene: an interview with Sally Bloomfield

Allergies occur when the body overreacts to substances in our environment, such as pollen, dust mites and so forth. What happens is that when we are exposed to these potential threats, the immune system should react, deal with it, and then shut down.

26 Oct 2012

Feinstein Institute to study overall impact of WTC disaster on responders

The Feinstein Institute for Medical Research has been awarded a $1 million grant from the World Trade Center Health Program, which is administered by the National Institute for Occupational Safety and Health, part of the US Centers for Disease Control and Prevention, the National Institute for Occupational Safety and Health and Safety to comprehensively study the overall physical, mental and socioeconomic impact of the World Trade Center (WTC) disaster on responders, as well as identify the linkage between socioeconomic status and health among all occupations of WTC responders.

26 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA (adalimumab) ULTRA 1 and ULTRA 2 studies.

23 Oct 2012

Possible overlap exists between inflammatory bowel disease and IBS

Research unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas suggests a possible overlap of symptoms of two prevalent GI disorders: irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) and further suggests a possible link between subtle GI tract inflammation and IBS symptoms-a link that is also the focus of the first systemic review of the literature on this topic and an editorial both published in this month's American Journal of Gastroenterology.

23 Oct 2012

Ustekinumab shows positive results in decreasing debilitating effects of Crohn's Disease

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San Diego, School of Medicine.

18 Oct 2012

Gothenburg researchers aim to discover new methods for treatment of childhood obesity

By studying intestinal flora in newborn children, Professor Fredrik Bäckhed and his team of researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, aim to discover new methods to treat childhood obesity.

17 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

Researchers identify molecular emergency brake in charge of regulating self-digestion

Almost everything that happens inside a cell, including autophagy, is tightly regulated on a biochemical level. Like that, the cell makes sure that processes only take place when they are needed and that they are shut off when the need has expired. "Inside the cell, there exists a network of molecules. Between them, information is constantly being exchanged," says Schmitz, head of the research group "Systems-oriented Immunology and Inflammation Research" at HZI, who also holds a chair at the Otto von Guericke University in Magdeburg.

15 Oct 2012

Study finds how MAIT cells recognize products of vitamin B synthesis from bacteria and yeast

An Australian research team has discovered how specialised immune cells recognise products of vitamin B synthesis that are unique to bacteria and yeast, triggering the body to fight infection.

11 Oct 2012

Chronic kidney disease changes the composition of intestinal bacterial microbes

Chronic kidney disease changes the composition of intestinal bacterial microbes that normally play a crucial role in staving off disease-causing pathogens and maintaining micronutrient balance, according to UC Irvine researchers.

10 Oct 2012

Coffee consumption activates bowel motility after elective colonic surgery

Patients who drank coffee, rather than water, after bowel surgery to remove a part of their colon experienced a quicker return to bowel movements and tolerance of solid food.

9 Oct 2012

Novel technology can identify potential biomarkers of ulcerative colitis

Scientists from the Florida campus of The Scripps Research Institute have developed a novel technology that can identify, in animal models, potential biomarkers of ulcerative colitis, a type of inflammatory bowel disease that affects the lining of the colon.

4 Oct 2012

Researchers identify IL-27 molecule involved in counterbalancing the immune system attack

We couldn't live without our immune systems, always tuned to detect and eradicate invading pathogens and particles. But sometimes the immune response goes overboard, triggering autoimmune diseases like lupus, asthma or inflammatory bowel disease.

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

Abbott receives FDA approval for Humira to treat ulcerative colitis

The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.

29 Sep 2012

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.

28 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012